메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Gaurav Prakash (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Arihant Jain (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Kamalkant Sahu (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Amanjit Bal (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Charanpreet Singh (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Rajender Basher (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Harmandeep Singh (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Kundan Mishra (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Aditya Jandial (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Deepesh Lad (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Alka Khadwal (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Radhika Srinivasan (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Ashim Das (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Neelam Varma (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Subhash Varma (Postgraduate Institute of Medical Education and Research, Chandigarh, India) Pankaj Malhotra (Postgraduate Institute of Medical Education and Research, Chandigarh, India)
저널정보
대한혈액학회 Blood Research Blood Research Vol.56 No.3
발행연도
2021.9
수록면
134 - 140 (7page)
DOI
10.5045/br.2021.2021039

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background This study evaluated the outcomes of patients with refractory/relapsed Hodgkin lymphoma (RRHL) treated with a bendamustine-based regimen in combination with ifosfamide, etoposide, and vinorelbine (VIBE). Methods Consecutive RRHL patients who were treated with the VIBE regimen were identified and studied for clinicopathologic characteristics, response to VIBE regimen, event-free survival (EFS), and feasibility of an autologous stem-cell transplant (autoSCT). Results In total, 24 patients received the VIBE regimen, and a median of 3 cycles were administered. In this cohort, 80% of the patients had received ≥2 prior lines of therapy. The overall and complete response rates with VIBE were 79% and 42%, respectively. After a median follow-up (following VIBE regimen) of 14 months (range, 3?76), the 3-year EFS and OS were 46% and 74%, respectively. Of the eligible patients, 92% underwent successful AutoSCT. The mean CD34+ cell count in the autograft was 5.5×106 /kg (SD 2.07). Neutropenia was the commonest hematologic toxicity and it was observed in 42% of the patients. However, only 9% of the patients developed grade III/IV febrile neutropenia. Chemotherapy-induced nausea and vomiting were the second most common grade III/IV toxicities in our cohort of patients. Conclusion In this retrospective analysis, the combination regimen, VIBE, has shown good efficacy in heavily pre-treated patients with RRHL without compromising stem cell collection. These encouraging results provide a rationale for further development of this regimen.

목차

등록된 정보가 없습니다.

참고문헌 (17)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0